Margin involvement at prostatectomy for clinically localized prostate cancer: Does a low-risk group exist? - Abstract

PURPOSE: To determine whether additional pathology details may provide risk stratification for patients with involved surgical margins at radical prostatectomy (RP).

METHODS AND MATERIALS:Eligible patients underwent RP between 2003 and 2010. Patients with preoperative prostate-specific antigen (PSA) ≥20, follow-up < 12 months, lymph node or seminal vesicle involvement, or who received radiation therapy or hormone therapy prior to PSA relapse were excluded. Surgical specimens were reviewed by a study pathologist, blinded to outcomes. Survival analysis methods were employed to assess disease control and survival rates, as well as association of patient-, tumor-, and treatment-specific factors for endpoints.

RESULTS: Of 355 RP cases, 279 patients were eligible for the present analysis. At a median follow-up of 53 months (range, 16-127), 31/114 (27%) of patients with involved surgical margins experienced PSA relapse, as compared with 7/165 (4%) for negative margins (hazard ratio, 4.997; 95% confidence interval, 2.425-10.296; P < .0001). Detailed pathology review demonstrated associations between PSA relapse and Gleason score at RP, extent of margin involvement (width), capsule penetration, and perineural invasion. Subgroup analysis identified low risk (4%) of 5-year PSA relapse for patients with Gleason ≤ 6 mm and margin width ≤ 4 mm (single maximal or cumulative). All subgroups with higher Gleason score or wider margin were associated with >20% risk of PSA relapse at 5 years.

CONCLUSIONS: Within the present study, Gleason score, 6 patients with margin width ≤ 4 mm appear to have low rates of early PSA relapse following RP. Low-grade cases with larger extent of margin involvement or higher risk Gleason score patients with any margin involvement have high rates of early PSA relapse.

Written by:
Watkins JM, Laszewski M, Watkins PL, Dufan TA, Adducci C.   Are you the author?
Department of Radiation Oncology, Carver School of Medicine, University of Iowa, Iowa City, Iowa; Bismarck Cancer Center, Bismarck, North Dakota; Department of Pathology, St. Alexius Medical Center, Bismarck, North Dakota; Department of Pediatrics, Carver School of Medicine, University of Iowa, Iowa City, Iowa; Department of Urology, Prairie Lakes Specialty Clinic, Watertown, South Dakota.

Reference: Pract Radiat Oncol. 2015 Jan-Feb;5(1):e31-6.
doi: 10.1016/j.prro.2014.04.005

PubMed Abstract
PMID: 25413418 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.